Here are the 424B prospectus supplements from Alto Neuroscience Inc. (ANRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. is conducting a primary underwritten offering of 3,776,436 shares of common stock at $26.48 per share, for an aggregate offering price of $100,000,025.28. Underwriting discounts are $1.4564 per share, yielding $94,500,023.89 in proceeds before expenses and estimated net proceeds of approximately $93.9 million.
The company plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including an additional planned Phase 3 monotherapy trial in treatment resistant depression, and for general working capital purposes.
Cash, cash equivalents and restricted cash were preliminarily estimated at $244.2 million as of June 30, 2026. Shares outstanding are expected to increase from 35,052,731 as of March 31, 2026 to 38,829,167 after the offering, which the company calculates will result in immediate dilution of $17.80 per share to new investors relative to the adjusted net tangible book value.